What is the 13F Pro Quality Score for VERU?

13F Pro ranks VERU INC. (VERU) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VERU's current score at https://13fpro.ai/research/VERU (free sign-up required for the full ranking).

Where does 13F Pro source VERU data?

All VERU INC. fundamentals and ownership data come directly from SEC EDGAR. VERU INC. files with the SEC under CIK 863894. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VERU in?

VERU INC. (VERU) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VERU research updated on 13F Pro?

VERU's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VERU INC.(VERU)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 863894 VERU stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VERU Stock Analysis & AI Quality Score

AI stock analysis and institutional research for VERU INC. (VERU), a Healthcare sector company. VERU is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), VERU INC. reports net income of $-2.7M, free cash flow of $-8.9M. Top institutional holders of VERU by reported 13-F value include Alyeska Investment Group, L.P., VANGUARD CAPITAL MANAGEMENT, OPPENHEIMER & CO, based on the most recent SEC filings. VERU trades on the Nasdaq exchange and files with the SEC under CIK 863894. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VERU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VERU INC. directly from SEC EDGAR. VERU INC.'s 13F Pro composite quality score has ranged between 6 and 54 since 2021, currently 10.4 — a declining long-term trajectory across 13 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-2.7M

Free Cash Flow

Q2 2026

$-8.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-57.1% YoY

$16.9MFY 2024

FY20 $42.6MFY21 $61.3MFY22 $39.4MFY24 $16.9M

Net Income

+54.9% YoY

$-37.8MFY 2024

FY20 $-19.0MFY21 $7.4MFY22 $-83.8MFY24 $-37.8M

Operating Income

+56.5% YoY

$-36.2MFY 2024

FY20 $-14.7MFY21 $13.0MFY22 $-83.2MFY24 $-36.2M

EPS (Diluted)

—FY 2024

FY20 $-0.28FY21 $0.09FY22 $-1.05FY24 —

Total Assets

-55.4% YoY

$60.4MFY 2024

FY20 $51.5MFY21 $178.1MFY22 $135.4MFY24 $60.4M

Total Debt

—FY 2024

FY20 —FY21 —FY22 —FY24 —

Op. Cash Flow

+54.4% YoY

$-21.7MFY 2024

FY20 $-1.9MFY21 $-15.6MFY22 $-47.5MFY24 $-21.7M

Metric	FY 2024	FY 2022	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	$16.9M -57.1%	$39.4M -35.8%	$61.3M +43.8%	$42.6M +168.5%	$15.9M +16.2%	$13.7M
Net Income	$-37.8M +54.9%	$-83.8M -1233.0%	$7.4M +139.0%	$-19.0M +20.7%	$-23.9M -262.0%	$-6.6M
Operating Income	$-36.2M +56.5%	$-83.2M -741.5%	$13.0M +188.0%	$-14.7M +29.3%	$-20.9M -145.7%	$-8.5M
EPS (Diluted)	—	$-1.05 -1266.7%	$0.09 +132.1%	$-0.28	—	$-0.25
Total Assets	$60.4M -55.4%	$135.4M -24.0%	$178.1M +245.6%	$51.5M +6.4%	$48.5M -12.4%	$55.3M
Total Debt	—	—	—	—	$1.8M	—
Operating Cash Flow	$-21.7M +54.4%	$-47.5M -205.1%	$-15.6M -706.7%	$-1.9M +83.3%	$-11.5M -1274.7%	$982.9K

AI Insight: VERU Financial Trends

VERU swung to profitability in Q3 2025 but reversed to losses in Q4 2025 and Q1 2026, with equity volatility masking underlying cash burn.

• Net income briefly turned positive at $1M in Q3 2025, ending five consecutive quarters of losses, before deteriorating to $-3M in Q1 2026.

• Equity collapsed from $38M (Q2 2024) to $15M (Q2 2025), recovering to $37M in Q4 2025, then contracting again to $35M in Q1 2026.

• Operating cash flow remained deeply negative in all eight quarters, ranging from $-4M to $-11M, with no sustainable improvement.

⚠ Profitability spike in Q3 2025 ($1M net income) proved unsustainable; losses resumed in Q4 2025 and Q1 2026, questioning durability.

⚠ Q4 2025 equity jumped to $37M from $18M—likely capital raise or accounting adjustment—but eroded to $35M by Q1 2026.

⚠ Persistent negative operating cash flow suggests business model cannot fund operations; runway depletion risk accelerating.

AI Insight: VERU Ratio Trends

VERU remains deeply unprofitable with negative ROIC across nearly all periods; a brief Q3 2025 profit spike was immediately reversed.

• ROE deteriorated from -116.6% in Q2 2024 to -191.2% in Q2 2025, then partially recovered to -31.5% in Q1 2026—still deeply negative.

• ROIC turned positive at 25.5% in Q3 2025 but collapsed to -58.4% in Q4 2025 and -83.0% in Q1 2026, indicating unsustainable profitability.

⚠ Only Q3 2025 showed positive returns (ROIC 25.5%, ROE 31.7%); Q4 2025 and Q1 2026 reversed sharply—identify whether Q3 was one-time or structural.

⚠ ROA declined from -25.4% in Q1 2026 TTM baseline; sustained negative asset returns suggest core operations remain unprofitable.

Get alerted when VERU's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VERU INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VERU

Alyeska Investment Group, L.P.
$2.2M1,000,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2M539,382 sh
OPPENHEIMER & CO INC
$433.8K196,300 sh
GEODE CAPITAL MANAGEMENT, LLC
$408.1K184,622 sh
Summit Financial, LLC
$335.4K151,783 sh
MILLENNIUM MANAGEMENT LLC
$332.4K150,401 sh
Ikarian Capital, LLC
$295.1K133,517 sh
BlackRock, Inc.
$252.3K114,169 sh
GROUP ONE TRADING, L.P.
$218.1K98,700 sh
VANGUARD FIDUCIARY TRUST CO
$178.2K80,653 sh

Fund	Value	Shares
Alyeska Investment Group, L.P.	$2.2M	1,000,000
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	539,382
OPPENHEIMER & CO INC	$433.8K	196,300
GEODE CAPITAL MANAGEMENT, LLC	$408.1K	184,622
Summit Financial, LLC	$335.4K	151,783
MILLENNIUM MANAGEMENT LLC	$332.4K	150,401
Ikarian Capital, LLC	$295.1K	133,517
BlackRock, Inc.	$252.3K	114,169
GROUP ONE TRADING, L.P.	$218.1K	98,700
VANGUARD FIDUCIARY TRUST CO	$178.2K	80,653

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VERU on your watchlist

Track score changes the day VERU INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VERU a good stock to buy?

13F Pro's AI-powered analysis of VERU INC. (VERU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VERU are available on the VERU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VERU?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VERU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VERU INC.'s investment landscape.